medigraphic.com
ISSN 2007-932X (Electronic)
Órgano Oficial de Difusión de la Comisión Nacional de Arbitraje Médico

2022, Number 4

<< Back Next >>

Rev CONAMED 2022; 27 (4)

Effectiveness of vaccines against COVID-19 applied to health personnel

Hernández PF, Martínez SVN, Aparicio BMM

Language: Spanish
References: 23
Page: 167-174
PDF size: 117.40 Kb.


ABSTRACT

Introduction: vaccines against COVID-19 have already proven their efficacy, but their effectiveness is still unknown. Objective: to determine the effectiveness of the different vaccines in health personnel to prevent COVID-19. Material and methods: cohort study. All health personnel vaccinated against SARS-CoV-2 and who treated patients with COVID-19 were considered and compared with unvaccinated health personnel. Were questioned about the diagnosis of COVID-19 corroborated by PCR or antigen testing, and its complications. Statistical analysis: for the determination of effectiveness, the formula: EV = (1 - OR) × 100. Results: 340 health workers were studied; 325 vaccinated and 15 unvaccinated. Of 325 vaccinated with the first dose, 8 were positive for SARS-CoV-2, second dose, 35 of 286 and booster in 272, 50 tested positive, 4 of 15 unvaccinated tested positive. The effectiveness for the first dose was 97.5%, the second 95.2% and the booster 9.91%. Conclusions: the effectiveness of the vaccine against mild COVID-19 in health personnel vaccinated in the first dose is high, it decreases a little for the 2nd dose but drops dramatically for the booster to only 9.91%.


REFERENCES

  1. WHO Coronavirus (COVID-19) Dashboard [Internet] Global situación. [Consultada el día 21 de abril del 2022] Disponible en: https://covid19.who.int/

  2. Secretaría de Salud [Internet] México. [Consultada el día 21 de abril del 2022] Disponible en: ttps://www.gob.mx/salud/prensa/309-mexico-rebasa-59-millones-de-vacunas-aplicadas-contra-covid-19

  3. COVID-19 Tablero México - CONACYT - CentroGeo [Internet] México. [Consultada el día 20 de abril del 2022] Disponible en: https://datos.covid-19.conacyt.mx/

  4. Informes sobre el personal de Salud COVID19 en México [Internet] México. [Consultada el día 20 de abril del 2022] Disponible en: https://coronavirus.gob.mx ' personal-de-salud

  5. Luzuriaga JP, Marsico F, Garcia E, González V, Kreplak N, Pifano M et al. Impacto de la aplicación de vacunas contra COVID-19 sobre la incidencia de nuevas infecciones por SARS-COV-2 en PS de la Provincia de Buenos Aires. SciELO Preimpresion. Disponible en: https://doi.org/10.1590/SciELOPreprints.2068

  6. Clínica Mayo.org [Internet] Estados Únicos. [Consultada el 30 de agosto del 2021] Disponible en: https://www.mayoclinic.org/es-es/diseases-conditions/coronavirus/in-depth/different-types-of-covid-19-vaccines/art-20506465

  7. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021; 384 (15): 1412-1423. doi: 10.1056/NEJMoa2101765

  8. Demonbreun AR, Sancilio A, Velez ME, Ryan DT, Pesce L, Saber R et al. COVID-19 mRNA vaccination generates greater immunoglobulin g levels in women compared to men. J Infect Dis. 2021; 224 (5): 793-797. Available in: https://doi.org/10.1093/infdis/jiab314

  9. Voysey M, Costa CSA, Madhi SA, Weckx LY, Folegatti PM, Aley PK et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021; 397: 99-111. Available in: https://doi.org/10.1016/ S0140-6736(20)32661-1

  10. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383 (27): 2603-2615. doi: 10.1056/NEJMoa2034577.

  11. Frenck RW Jr, Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S et al. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. N Engl J Med. 2021; 385 (3): 239-250. doi: 10.1056/NEJMoa2107456.

  12. Lauring AS, Tenforde MW, Chappell JD, Gaglani M, Ginde AA, McNeal T et al. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ. 2022; 376: e069761. Available in: http://dx.doi.org/10.1136/bmj-2021-069761

  13. Barda N, Dagan N, Cohen C, Hernán MA, Lipsitch M, Kohane IS et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet. 2021; 398: 2093-2100. Available in: https://doi.org/10.1016/S0140-6736(21)02249-2

  14. Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. N Engl J Med. 2022; 386 (16): 1532-1546. doi: 10.1056/NEJMoa2119451

  15. Hammerman A, Sergienko R, Friger M, Beckenstein T, Peretz A, Netzer D et al. Effectiveness of the BNT162b2 vaccine after recovery from Covid-19. N Engl J Med. 2022; 386 (13): 1221-1229.

  16. Ireland G, Whitaker H, Ladhani SN, Baawuah F, Subbarao V, Linley E et al. Serological responses to COVID-19 booster vaccine in England. medRxiv preprint 2021. doi: https://doi.org/10.1101/2021.11.22.21266692

  17. Maunder RG, Heeney ND, Kiss A, Hunter JJ, Jeffs LP, Ginty L et al. Psychological impact of the COVID-19 pandemic on hospital workers over time: Relationship to occupational role, living with children and elders, and modifiable factors. Gen Hosp Psychiatry. 2021; 71: 88-94. doi: 10.1016/j.genhosppsych.2021.04.012.

  18. Ebinger JE, Fert-Bober J, Printsev I, Wu M, Sun N, Prostko JC et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat Med. 2021; 27 (6): 981-984. Available in: https://doi.org/10.1038/s41591-021-01325-6

  19. Thompson MG, Burgess JL, Naleway AL, Tyner H, Yoon SK, Meece J et al. Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. N Engl J Med. N Engl J Med. 2021; 385 (4): 320-329. doi: 10.1056/NEJMoa2107058

  20. Korang SK, von Rohden E, Veroniki AA, Ong G, Ngalamika O, Siddiqui F et al. Vaccines to prevent COVID-19: a living systematic review with trial sequential analysis and network meta-analysis of randomized clinical trials. PLoS ONE. 2022; 17 (1): e0260733. Available in: https://doi.org/10.1371/journal.pone.0260733

  21. Spitzer A, Angel Y, Marudi O, Zeltser D, Saiag E, Goldshmidt H et al. Association of a third dose of BNT162b2 vaccine with incidence of SARS-CoV-2 infection among health care workers in Israel. JAMA. 2022; 327 (4): 341-349. doi: 10.1001/jama.2021.23641.

  22. Pilishvili T, Gierke R, Fleming-Dutra KE, Farrar JL, Mohr NM, Talan DA et al. Effectiveness of mRNA Covid-19 Vaccine among U.S. health care personnel. N Engl J Med. 2021; 385:e90. doi: 10.1056/NEJMoa2106599.

  23. Keehner J, Horton LE, Binkin NJ, Laurent LC; SEARCH Alliance, Pride D, et al. Resurgence of SARS-CoV-2 Infection in a Highly Vaccinated Health System Workforce. N Engl J Med. 2021; 385 (14): 1330-1332. doi: 10.1056/NEJMc2112981.




2020     |     www.medigraphic.com